ImmunityBio, Inc. Common Stock

IBRX trades with a staggering 36.13% short interest—nearly triple the market average—against a $7.5B market cap, creating powder-keg squeeze potential if momentum shifts. The RSI of 44.7 sits in neutral territory, neither oversold nor overbought, suggesting the stock lacks extreme conviction in either direction despite the heavy short load. Notably, the company trades without a meaningful P/E ratio, indicating either recent profitability struggles or losses, which undercuts the bullish narrative many shorts might fear. The biotech's position below its 52-week high combined with massive short exposure and marginal technicals creates an asymmetric risk setup—material short covering could spark violent rallies, but fundamental earnings power remains questionable.